Fig. 3From: Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectivesSurgical and pathological outcomes of neoadjuvant ICI alone or with chemotherapy studies. Data is stratified by complete response (pCR) rate (%), major pathologic response (MPR) rate (%), and the resection rate (%)Back to article page